Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
Researchers have unveiled a novel immune mechanism by which tandem kinases combat pathogen invasion: an atypical NLR protein, ...
Depending on which tyrosine residue of the two receptors ... et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137–1149 (2006 ...
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
"Insulin binding to InsRα derepresses the tyrosine kinase activity of the β-subunit ... The results of this study identify ...
Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in ...
Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback